Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital | Zendy

Riina RautemaaRichardson | Zendy; Vilma Rautemaa | Zendy; F Al-Wathiqi | Zendy; CB Moore | Zendy; Linda Craig | Zendy; Tim Felton | Zendy; Eavan G. Muldoon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital

Author(s) -

Riina RautemaaRichardson,

Vilma Rautemaa,

F Al-Wathiqi,

CB Moore,

Linda Craig,

Tim Felton,

Eavan G. Muldoon

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky360

Subject(s) - micafungin , medicine , guideline , antifungal , invasive candidiasis , intensive care medicine , intensive care unit , amphotericin b , fluconazole , pathology , dermatology

A concise invasive candidosis guideline (based on the ESCMID candidaemia guideline) utilizing an informative biomarker [serum β-1-3-d-glucan (BDG)] was developed in 2013 by an antifungal stewardship (AFS) team and implemented with the help of an AFS champion in 2014. The main aims of the AFS programme were to reduce inappropriate use of antifungals and improve patient outcomes. The aim of this project was to evaluate the compliance of the ICU teams with the invasive candidosis guideline and the impact of the AFS programme on mortality and antifungal consumption on the ICUs (total of 71 beds).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research